Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience.
Chromosomal abnormalities
Cytogenetics
Non-Hodgkin Lymphoma
Waldenström Macroglobulinemia
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
07
02
2024
accepted:
19
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
The prognostic and predictive role of specific gene mutations in Waldenström Macroglobulinemia (WM) is well-ascertained whereas the clinical impact of chromosome aberrations is far less known. Recent work has provided initial evidence for an adverse prognostic impact of some aberrations, such as del(6q), while other studies suggest a possible relationship between some clinical features (e.g. advanced age and/or inflammatory status) and specific cytogenetic abnormalities. To add to the still limited knowledge on WM cytogenetics and its clinical implications, we herein report our experience in a cohort of WM patients across 23 years. Based on our retrospective study, we found that abnormal karyotype was more represented in older patients and maintained a statistically significant independence from other molecular, clinical, and biological features related to WM. The presence and number of cytogenetic aberrations correlated with inferior overall and progression-free survival outcomes regardless of the type of single chromosome aberration. Our data suggests that the role of the altered karyotype deserves to be further clarified especially in elderly WM patients, in whom cytogenetic abnormalities and disease biology appear to be characterized by a higher degree of complexity.
Identifiants
pubmed: 38687347
doi: 10.1007/s00277-024-05770-4
pii: 10.1007/s00277-024-05770-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720–1748
doi: 10.1038/s41375-022-01620-2
pubmed: 35732829
pmcid: 9214472
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163–4170
doi: 10.1182/blood-2008-08-174961
pubmed: 19196866
Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J et al (2020) Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol 38(11):1198–1208
doi: 10.1200/JCO.19.02314
pubmed: 32083995
pmcid: 7351339
Garcia-Sanz R, Varettoni M, Jiménez C, Ferrero S, Poulain S, San-Miguel JF, Guerrera ML et al (2023) Report of Consensus Panel 3 from the 11th International workshop on Waldenström’s Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström’s Macroglobulinemia. Semin Hematol 60(2):90–96
doi: 10.1053/j.seminhematol.2023.03.007
pubmed: 37099028
García-Sanz R, Dogliotti I, Zaccaria GM, Ocio EM, Rubio A, Murillo I, Escalante F et al (2021) 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol 192(5):843–852
doi: 10.1111/bjh.17028
pubmed: 32780894
Elessa D, Debureaux PE, Villesuzanne C, Davi F, Bravetti C, Harel S, Talbot A, Oksenhendler et al (2022) Inflammatory Waldenström’s macroglobulinaemia: A French monocentric retrospective study of 67 patients. Br J Haematol. 197(6):728–735
doi: 10.1111/bjh.18157
pubmed: 35393650
Danesin N, Lo Schirico M, Scapinello G, Grassi A, Riva M, Berno T et al (2023) Waldenström macroglobulinemia in very elderly (≥75-year-old) Patients: A 33-year-retrospective cohort study in an italian university hospital. Hemasphere 7(10):e964
doi: 10.1097/HS9.0000000000000964
pubmed: 37799344
pmcid: 10550041
García-Sanz R, Hunter ZR, Poulain S, Varettoni M, Owen RG (2023) New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia. Expert Rev Hematol 16(11):835–847
doi: 10.1080/17474086.2023.2270779
pubmed: 37905549
Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, Pérez J, Drandi D, Puig N, Gilestro M, García-Álvarez M, Owen R, Jurczak W, Tedeschi A, Leblond V, Kastritis E, Kersten MJ, D’Sa S, Kaščák M, Willenbacher W, Roccaro AM, Poulain S, Morel P, Kyriakou C, Fend F, Vos JMI, Dimopoulos MA, Buske C, Ferrero S, García-Sanz R (2023) Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia. Leukemia 37(2):388–395
doi: 10.1038/s41375-022-01762-3
pubmed: 36435884
Krzisch D, Guedes N, Boccon-Gibod C, Baron M, Bravetti C, Davi F, Armand M, Smagghe L, Caron J, Bernard OA, on behalf the FILO (French Innovative Leukemia Organization) group et al (2021) Cytogenetic and molecular abnormalities in Waldenström’s macroglobulinemia patients: Correlations and prognostic impact. Am J Hematol. 96(12):1569–1579
doi: 10.1002/ajh.26339
pubmed: 34462944
Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D’Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J (2023) Report of consensus panel 1 from the 11
doi: 10.1053/j.seminhematol.2023.03.005
pubmed: 37099027
Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblondon V, Groupe Français d’Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW), Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS), Groupe d’Etude des Lymphomes de l’Adulte (GELA) (2013) Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 98(4):649–54
doi: 10.3324/haematol.2012.070458
pubmed: 23065509
pmcid: 3659998
McGowan-Jordan J, Hastings RJ, Moore S, International Standing Committee on Human Cytogenomic Nomenclature (2020) ISCN 2020: an Internatonal System for Human Cytogenomic Nomenclature. Karger
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 121(13):2522–2528
doi: 10.1182/blood-2012-09-457101
pubmed: 23355535
Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 172(5):735–44
doi: 10.1111/bjh.13897
pubmed: 26659815
Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, Gallì A, Porta MGD, Boveri E, Arcaini L, Candido C, Paulli M, Cazzola M (2017) Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica 102(12):2077–2085
doi: 10.3324/haematol.2017.172718
pubmed: 28983055
pmcid: 5709107
Walewska R, Eyre TA, Barrington S, Brady J, Fields P, Iyengar S, Joshi A, Menne T, Parry-Jones N, Walter H, Wotherspoon A, Linton K, BSH Committee (2024) Guideline for the diagnosis and management of marginal zone lymphomas: A british society of haematology guideline. Br J Haematol 204(1):86–107
doi: 10.1111/bjh.19064
pubmed: 37957111
Florence Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Groupe Français d’Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW), Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS), Groupe d’Etude des Lymphomes de l’Adulte (GELA) et al (2013) Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 98(4):649–54
doi: 10.3324/haematol.2012.070458
pubmed: 23065509
pmcid: 3659998
Xiong W, Wang T, Yu Y, Jiao Y, Chen J, Wang Y, Li C et al (2023) Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia in Chinese patients. Chin Med J (Engl) 136(10):1240–1242
doi: 10.1097/CM9.0000000000002656
pubmed: 37057735